Lifeboat Foundation

Trapped light amplified the material’s magnetism 10x, enough to change its visible properties.

Laser-generated pulling forces are over 1,000 times stronger than those driving solar sails.

Surprisingly, the organoids were still healthy when they returned from orbit a month later, but the cells had matured faster compared to identical organoids grown on Earth—they were closer to becoming adult neurons and were beginning to show signs of specialization. The results, which could shed light on potential neurological effects of space travel, were published on October 23, 2024, in Stem Cells Translational Medicine.

“The fact that these cells survived in space was a big surprise,” says co-senior author Jeanne Loring, PhD, professor emeritus in the Department of Molecular Medicine and founding director of the Center for Regenerative Medicine at Scripps Research. “This lays the groundwork for future experiments in space, in which we can include other parts of the brain that are affected by neurodegenerative disease.”

On Earth, the team used stem cells to create organoids consisting of either cortical or dopaminergic neurons, which are the neuronal populations impacted in multiple sclerosis and Parkinson’s disease—diseases that Loring has studied for decades. Some organoids also included microglia, a type of immune cell that is resident within the brain, to examine the impact of microgravity on inflammation.

Continue reading “Effects of microgravity on human iPSC-derived neural organoids on the International Space Station” »

From ‘Star Trek’ and ‘Star Wars’ to superheroes and clones, it’s set to be a busy 2025 on screens both big and small.

After revolutionizing global internet access, Elon Musk’s Starlink is poised to take smartphone connectivity to the next level. The ambitious satellite service will soon enable users to make calls from virtually anywhere on the planet, all without the need for specialized hardware.

Starlink, a division of SpaceX, has announced its plans to introduce Direct-to-Cell, a groundbreaking feature that uses its vast satellite network to allow voice calls on regular smartphones. What sets this apart is its simplicity—there’s no need for modifications to your device. As long as your phone is LTE-compatible, you’re ready to connect.

This innovation could fundamentally change how we think about mobile communication. Imagine being able to make calls from the remotest corners of the Earth—whether you’re deep in a rainforest, sailing in the middle of the ocean, or trekking across deserts—with no cell towers in sight. Starlink’s satellite system makes this scenario entirely possible.

Mount Sinai researchers discovered that harmine, a beta cell regenerative drug, may transform alpha cells into beta cells, offering scalable diabetes treatment options for millions.

Researchers and bioinformaticians at the Icahn School of Medicine at Mount Sinai have unveiled new insights into the mechanisms behind human beta cell regenerative drugs, offering a potential breakthrough for the over 500 million people worldwide living with diabetes. These findings, recently published in Cell Reports Medicine, could mark a significant step forward in diabetes treatment.

Diabetes occurs when pancreatic beta cells lose their ability to produce insulin, a hormone critical for maintaining healthy blood sugar levels. Despite significant advancements, there are still no widely scalable therapeutic solutions capable of addressing the global diabetes crisis.

A rare black moon, the second new moon of December, will rise over Texas tonight.

USA-based clinical-stage biopharma Traws Pharma (Nasdaq: TRAW) saw its shares leap more than 150% to $12.57 as it announced progress in the development of its investigational one-dose influenza (flu) investigational therapy, tivoxavir marboxil for treatment of H5N1 bird flu. A Phase I trial tested tivoxavir marboxil in healthy adults who didn’t have the flu.

Traws Pharma expects to begin a Phase II study in the first half of 2025 as it expands its influenza program in response to the bird flu threat. The virus has been detected in dairy cattle in the USA. since March 2024, resulting in infections in over 60 people across eight states.

“The spread of avian influenza in wild and domestic animal populations including mammals, brings increasing risk for adaptation to humans and subsequent spread in the population” said Traws Pharma’s chief medical officer Dr Robert Redfield, a former Director of the US Centers for Disease Control and Prevention (CDC). “Bird flu is an occupational hazard for poultry and dairy workers. With increasing numbers of human infections and recent reports of severe cases, we should be alert to the rising potential for epidemic or pandemic spread of bird flu,” he added.

Researchers at the Icahn School of Medicine at Mount Sinai have been awarded a $21 million grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH), to further advance understanding of an aging-related hormone known as follicle-stimulating hormone (FSH), including its potential role in obesity, osteoporosis, and Alzheimer’s disease. The work could lead to the development of new treatments for these and other conditions involving aging.

This is a collaborative effort with the NIA, led by Mone Zaidi, MD, PhD, Director of the Center for Translational Medicine and Pharmacology at Icahn Mount Sinai, and Clifford J. Rosen, MD, at the MaineHealth Institute for Research in Scarborough, Maine. Dr. Zaidi and Dr. Rosen are Program Directors, and principal investigators of individual projects are Anne Schafer, MD, at the University of California in San Francisco, as well as scientists at Icahn Mount Sinai, including Tony Yuen, PhD, Associate Professor and Research Director of the Center for Translational Medicine and Pharmacology, and Daria Lizneva, MD, PhD, Associate Professor of Pharmacological Sciences. Together, the investigators will work toward translating their findings into viable treatments for patients.

Continue reading “Icahn School of Medicine at Mount Sinai Awarded $21 Million NIH Grant to Advance Understanding of Aging-Related Hormone” »